Wei Lin

Wei Lin serves as the Chief Medical Officer at Revolution Medicines since April 2023 and holds a board member position at 2seventy bio concurrently. Prior to these roles, Wei Lin was the Chief Medical Officer at Erasca, Inc. from January 2021 to April 2023 and had a significant tenure at Nektar Therapeutics as Senior Vice President and Head of Development. Wei Lin's extensive career includes various leadership roles in global development at Genentech, focusing on cancer immunotherapy. Experience also encompasses leadership positions at Roche, MD Anderson Cancer Center, and Massachusetts General Hospital. Wei Lin earned an MD from Harvard Medical School and a Bachelor's degree in Physics from Haverford College.